Berdazimer Gel Shows Promise in Treating Molluscum Contagiosum

Written By : Jacinthlyn Sylvia |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2023-10-11T10:00:00+05:30 | Updated On 11 Oct 2023 11:05 AM IST

For effective treatment of molluscum contagiosum (MC), a common skin infection caused by a poxvirus, a breakthrough may be on the horizon.

A recent clinical trial published in the Journal of the American Academy of Dermatology has revealed promising results for a novel topical gel, berdazimer gel 10.3%, as a potential treatment for MC.

The study, known as the B-SIMPLE trial, aimed to evaluate the efficacy and safety of berdazimer gel compared to a placebo vehicle. Over 1,500 patients, aged six months and older, with 3 to 70 mollusca lesions, participated in the 12-week trial. The gel was applied once daily to all MC lesions.

Berdazimer gel demonstrated superiority over the placebo vehicle, with a 30.0% complete lesion clearance rate compared to 19.8% in the placebo group at week 12. This significant difference underscores the potential of berdazimer gel as an effective treatment for MC.

Subgroup analyses further supported berdazimer's efficacy, showing positive outcomes across various demographic and baseline lesion count categories. This inclusivity suggests that the gel could be beneficial for a wide range of MC patients.

Additionally, berdazimer gel showed promise in achieving partial clearance of MC lesions. However, it's worth noting that some patients reported mild to moderate local skin reactions, such as application-site pain (18.7%) and erythema (11.7%). These reactions were generally well-tolerated.

Nonetheless, these findings offer hope for individuals suffering from MC, a condition characterized by small, pearly, or flesh-colored bumps on the skin that can be both physically uncomfortable and aesthetically distressing. An effective, well-tolerated treatment like berdazimer gel could potentially provide relief and improve the quality of life for those affected by this viral skin infection. While further research and clinical testing are needed, the B-SIMPLE trial results mark a significant step forward in the development of a much-needed therapeutic agent for molluscum contagiosum.

Reference:

Sugarman, J. L., Hebert, A., Browning, J. C., Paller, A. S., Stripling, S., Green, L. J., Cartwright, M., Enloe, C., Wells, N., & Maeda-Chubachi, T. (2023). Berdazimer Gel for Molluscum Contagiosum: An Integrated Analysis of 3 Randomized Controlled Trials. In Journal of the American Academy of Dermatology. Elsevier BV. https://doi.org/10.1016/j.jaad.2023.09.066

Journal of the American Academy of Dermatologymolluscum contagiosumBerdazimer gel

Source : Journal of the American Academy of Dermatology

Jacinthlyn Sylvia

Neuroscience Masters graduate

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751